Mutations in HBV DNA Polymerase Associated With Nucleos(t)ide Resistance Are Rare in Treatment-naive Patients

Clinical Gastroenterology and Hepatology

Volumn 12, Issue 8, 2014, Pages 1363-1370

  Vutien, Philip ^a,b   Trinh, Huy N ^c,d   Garcia, Ruel T ^c,d   Nguyen, Huy A ^d   Levitt, Brian S ^d   Nguyen, Khanh ^d   da Silveira, Eduardo ^d   Daugherty, Tami ^b   Ahmed, Aijaz ^b   Garcia, Gabriel ^b   Lutchman, Glen A ^b   Nguyen, Mindie H ^b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Pacific Health Foundation   (United States)

^d San Jose Gastroenterology   (United States)

Author keywords

ADV; Baseline; CHB; ETV; HBeAg; HBV; LAM; NA; Reverse; Rt; TDF; Transcriptase

Indexed keywords

ALCOHOL; DNA POLYMERASE; HEPATITIS B(E) ANTIGEN; NUCLEOSIDE ANALOG; DNA DIRECTED DNA POLYMERASE; VIRUS DNA; NUCLEOTIDE DERIVATIVE;

ADULT; AGED; ALCOHOL CONSUMPTION; ARTICLE; ASIAN; ASSAY; CHINESE; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DEMOGRAPHY; DRUG USE; ENVIRONMENTAL FACTOR; FAMILY HISTORY; FEMALE; GENE MUTATION; GENE SEQUENCE; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; PROSPECTIVE STUDY; QUESTIONNAIRE; RISK FACTOR; ADOLESCENT; ANTIVIRAL RESISTANCE; ENZYMOLOGY; GENETICS; GENOTYPING TECHNIQUE; HEPATITIS B, CHRONIC; ISOLATION AND PURIFICATION; MIDDLE AGED; MISSENSE MUTATION; PREVALENCE; UNITED STATES; VIROLOGY; YOUNG ADULT; HEPATITIS C; LIVER CIRRHOSIS; MULTICENTER STUDY; VIETNAMESE; VIRUS RESISTANCE;

ADOLESCENT; ADULT; AGED; CALIFORNIA; CROSS-SECTIONAL STUDIES; DNA, VIRAL; DNA-DIRECTED DNA POLYMERASE; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPING TECHNIQUES; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; MALE; MIDDLE AGED; MUTATION, MISSENSE; PREVALENCE; PROSPECTIVE STUDIES; SURVEYS AND QUESTIONNAIRES; YOUNG ADULT;

EID: 84904383750     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2013.11.036     Document Type: Article

References (38)

1. Ghany M.G., Doo E.C. Assessment and management of chronic hepatitis B. Infect Dis Clin North Am 2006, 20:63-79.
2. Keeffe E.B., Dieterich D.T., Pawlotsky J.M., et al. Chronic hepatitis B: preventing, detecting, and managing viral resistance. Clin Gastroenterol Hepatol 2008, 6:268-274.
3. McMahon B.J. Natural history of chronic hepatitis B. Clin Liver Dis 2010, 14:381-396.
4. Liaw Y.F., Sung J.J., Chow W.C., et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. NEngl J Med 2004, 351:1521-1531.
5. Keeffe E.B., Dieterich D.T., Han S.H., et al. Atreatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol 2008, 6:1315-1341. quiz 286.
6. Locarnini S. Primary resistance, multidrug resistance, and cross-resistance pathways in HBV as a consequence of treatment failure. Hepatol Int 2008, 2:147-151.
7. Zoulim F., Locarnini S. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology 2009, 137:1593-1608. e1-e2.
8. Aberle S.W., Kletzmayr J., Watschinger B., et al. Comparison of sequence analysis and the INNO-LiPA HBV DR line probe assay for detection of lamivudine-resistant hepatitis B virus strains in patients under various clinical conditions. JClin Microbiol 2001, 39:1972-1974.
9. Akarsu M., Sengonul A., Tankurt E., et al. YMDD motif variants in inactive hepatitis B carriers detected by Inno-Lipa HBV DR assay. JGastroenterol Hepatol 2006, 21:1783-1788.
10. Amini-Bavil-Olyaee S., Hosseini S.Y., Sabahi F., et al. Hepatitis B virus (HBV) genotype and YMDD motif mutation profile among patients infected with HBV and untreated with lamivudine. Int J Infect Dis 2008, 12:83-87.
11. Fung S.K., Mazzulli T., El-Kashab M., et al. Lamivudine-resistant mutation among treatment-naive hepatitis B patients is common and may be associated with treatment failure. Hepatology 2008, 48(Suppl 1):703A.
12. Han Y., Huang L.H., Liu C.M., et al. Characterization of hepatitis B virus reverse transcriptase sequences in Chinese treatment naive patients. JGastroenterol Hepatol 2009, 24:1417-1423.
13. Huang Z.M., Huang Q.W., Qin Y.Q., et al. YMDD mutations in patients with chronic hepatitis B untreated with antiviral medicines. World J Gastroenterol 2005, 11:867-870.
14. Jardi R., Rodrigeuz-Frias F., Buti M., et al. Mutations at HBV-Polymerase gene associated with entecavir resistance in patients not undergoing entecavir therapy. Hepatology 2006, 44:547A.
15. Kobayashi S., Ide T., Sata M. Detection of YMDD motif mutations in some lamivudine-untreated asymptomatic hepatitis B virus carriers. JHepatol 2001, 34:584-586.
16. Lampertico P., Vigano M., Facchetti F., et al. Effectiveness of entecavir for the treatment of NUC-naive chronic hepatitis B patients: a large multicenter cohort study in clinical practice. Hepatology 2008, 48:707A.
17. Lee C.Z., Lee H.S., Huang G.T., et al. Detection of YMDD mutation using mutant-specific primers in chronic hepatitis B patients before and after lamivudine treatment. World J Gastroenterol 2006, 12:5301-5305.
18. Liu B.M., Li T., Xu J., et al. Characterization of potential antiviral resistance mutations in hepatitis B virus reverse transcriptase sequences in treatment-naive Chinese patients. Antiviral Res 2010, 85:512-519.
19. Ludwig A.D., Goebel T., Adams O., et al. Primary resistance mutations against nucelos(t)ide analogues in treatment naive patients with HBV-infection. Hepatology 2008, 48:701A.
20. Matsuda M., Suzuki F., Suzuki Y., et al. Low rate of YMDD motif mutations in polymerase gene of hepatitis B virus in chronically infected patients not treated with lamivudine. JGastroenterol 2004, 39:34-40.
21. Mirandola S., Campagnolo D., Bortoletto G., et al. Large-scale survey of naturally occurring HBV polymerase mutations associated with anti-HBV drug resistance in untreated patients with chronic hepatitis B. JViral Hepat 2011, 18:e212-e216.
22. Nguyen M.H., Garcia R.T., Trinh H.N., et al. Prevalence of hepatitis B virus DNA polymerase mutations in treatment-naive patients with chronic hepatitis B. Aliment Pharmacol Ther 2009, 30:1150-1158.
23. Nguyen M.H., Trinh H.N., Garcia R.T., et al. Hepatitis B virus (HBV) reverse transcriptase mutation is rare in treatment-naive patients with chronic hepatitis B (CHB): a prospective multicenter study using INNO-LiPA HBV DR3 assay. Hepatology 2011, 54(Suppl 1):1080A.
24. Pollicino T., Isgro G., Di Stefano R., et al. Variability of reverse transcriptase and overlapping S gene in hepatitis B virus isolates from untreated and lamivudine-resistant chronic hepatitis B patients. Antivir Ther 2009, 14:649-654.
25. Pollicino T., Isgro G., DiStefano R., et al. Variability of the HBV Pol gene reverse transcriptase domain in viral isolates from untreated and lamivudine-resistance chronic hepatitis B patients. Hepatology 2007, 46:660A.
26. Salpini R., Svicher V., Cento V., et al. Characterization of drug-resistance mutations in HBV D-genotype chronically infected patients, naive to antiviral drugs. Antiviral Res 2011, 92:382-385.
27. Zollner B., Sterneck M., Wursthorn K., et al. Prevalence, incidence, and clinical relevance of the reverse transcriptase V207I mutation outside the YMDD motif of the hepatitis B virus polymerase during lamivudine therapy. JClin Microbiol 2005, 43:2503-2505.
28. Degertekin B., Hussain M., Tan J., et al. Sensitivity and accuracy of an updated line probe assay (HBV DR v.3) in detecting mutations associated with hepatitis B antiviral resistance. JHepatol 2009, 50:42-48.
29. Hepatitis B virus drug resistance mutations. Available at: Last update December 2011. Accessed January2013. http://www.questdiagnostics.com/testcenter/testguide.action?dc=TS_HBV_Genotype_BCP_Precore%26tabview=true.
30. Curtis M., Zhu Y., Borroto-Esoda K. Hepatitis B virus containing the I233V mutation in the polymerase reverse-transcriptase domain remains sensitive to inhibition by adefovir. JInfect Dis 2007, 196:1483-1486.
31. Sheen E., Trinh H.N., Nguyen T.T., et al. The efficacy of entecavir therapy in chronic hepatitis B patients with suboptimal response to adevofir. Aliment Pharmacol Ther 2011, 34:767-774.
32. Schildgen O., Sirma H., Funk A., et al. Variant of hepatitis B virus with primary resistance to adefovir. NEngl J Med 2006, 354:1807-1812.
33. Villet S., Pichoud C., Billioud G., et al. Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure. JHepatol 2008, 48:747-755.
34. Nguyen V.T., Law M.G., Dore G.J. Hepatitis B-related hepatocellular carcinoma: epidemiological characteristics and disease burden. JViral Hepat 2009, 16:453-463.
35. Rhee S.Y., Margeridon-Thermet S., Nguyen M.H., et al. Hepatitis B virus reverse transcriptase sequence variant database for sequence analysis and mutation discovery. Antiviral Res 2010, 88:269-275.
36. Margeridon-Thermet S., Shulman N.S., Ahmed A., et al. Ultra-deep pyrosequencing of hepatitis B virus quasispecies from nucleoside and nucleotide reverse-transcriptase inhibitor (NRTI)-treated patients and NRTI-naive patients. JInfect Dis 2009, 199:1275-1285.
37. Rodriguez C., Chevaliez S., Bensadoun P., et al. Characterization of the dynamics of hepatitis B virus resistance to adefovir by ultra-deep pyrosequencing. Hepatology 2013, 58:890-901.
38. Paik Y.H., Han K.H., Hong S.P., et al. The clinical impact of early detection of the YMDD mutant on the outcomes of long-term lamivudine therapy in patients with chronic hepatitis B. Antivir Ther 2006, 11:447-455.